CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas

BACKGROUND: Sunitinib is one of the first-line standard treatments for metastatic clear cell renal cell carcinoma (ccRCC) with a median time to progression shorter than 1 year. The objective is to discover predictive markers of response to adapt the treatment at diagnosis. METHODS: Prospective phase...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Dufies, Maeva, Giuliano, Sandy, Viotti, Julien, Borchiellini, Delphine, Cooley, Linsay S, Ambrosetti, Damien, Guyot, Mélanie, Ndiaye, Papa Diogop, Parola, Julien, Claren, Audrey, Schiappa, Renaud, Gal, Jocelyn, Frangeul, Antoine, Jacquel, Arnaud, Cassuto, Ophélie, Grépin, Renaud, Auberger, Patrick, Bikfalvi, Andréas, Milano, Gérard, Escudier, Bernard, Rioux-Leclercq, Nathalie, Porta, Camillo, Negrier, Sylvie, Chamorey, Emmanuel, Ferrero, Jean-Marc, Pagès, Gilles
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2017
Assuntos:
Translational Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5625677/
https://ncbi.nlm.nih.gov/pubmed/28850564
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2017.276
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados